Disease-Modifying Therapy
Cross-source consensus on Disease-Modifying Therapy from 1 sources and 3 claims.
1 sources · 3 claims
Benefits
Risks & contraindications
Highlighted claims
- Nusinersen, risdiplam, and onasemnogene abeparvovec have demonstrated efficacy as disease-modifying therapies for SMA. — Effects of physical therapy on motor ability in patients with spinal muscular atrophy III: a study protocol for a randomised controlled trial
- Patients may still have residual motor, respiratory, postural, and other functional challenges despite pharmacological treatment. — Effects of physical therapy on motor ability in patients with spinal muscular atrophy III: a study protocol for a randomised controlled trial
- Drug therapy can prolong life expectancy and optimize functional performance in SMA. — Effects of physical therapy on motor ability in patients with spinal muscular atrophy III: a study protocol for a randomised controlled trial